FDA pilot program aims to accelerate phase 1 trial approvals
The agency opens an expedited IND pathway to help U.S. early-stage trials keep pace with China.
The U.S. Food and Drug Administration has opened a pilot program designed to streamline the investigational new drug (IND) application process for phase 1 trials. The agency had teased the initiative over the summer and has now made it operational, according to a report from Fierce Biotech.
The program is intended to address sluggish early-stage clinical trial launches in the United States. By expediting the IND pathway, the FDA hopes to bring U.S. phase 1 trials closer to the pace seen in China, where trial initiation has generally been faster. The source does not provide details on specific eligibility criteria or timelines, so those remain unclear.
Overall, the pilot marks a regulatory effort to reduce friction in early drug development. The source notes only this single development, with no comparison to prior programs or independent commentary, so the full impact is yet to be measured.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.